Clinical Data ASCO26: AZ triplet makes waves in frontline liver cancer PharmaphorumEMERALD-3 suggests a triplet regimen based on AstraZeneca's Imfinzi and Imjudo could be practice-changing as a frontline hepatocellular carcinoma.OncologyRead full story pharminent June 2, 2026 (Last updated: June 4, 2026) Pharmaphorum EMERALD-3 suggests a triplet regimen based on AstraZeneca’s Imfinzi and Imjudo could be practice-changing as a frontline hepatocellular carcinoma. Oncology Read full story Post navigation Previous: CordenPharma inks AmbioPharm buyout to continue peptide production expansionNext: Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn Related Stories Clinical Data Novartis says MS pill succeeds in two large studies pharminent September 1, 2026 Clinical Data ESC 2026: Evolocumab explores new frontiers in CV disease prevention pharminent August 31, 2026 Clinical Data New data could widen use of AstraZeneca, Amgen immune disease drug pharminent August 27, 2026